论文部分内容阅读
目的:探讨胰高血糖素样肽-1(GLP-1)受体激动剂联合门冬胰岛素30对2型糖尿病患者控糖效果及体重的影响。方法:选取116例2型糖尿病患者为研究对象,随机数字表法分成研究组(A组,n=58)和对照组(B组,n=58)两组。B组予以门冬胰岛素30治疗方案,A组则采用门冬胰岛素30联合利拉鲁肽治疗方案,均持续治疗24周后观察疗效。比对两组患者治疗前后控糖指标、脂质生化指标及体重指数(BMI)等变化情况,记录其甲级血糖控制率、血糖总控制率及低血糖发生率差异。结果:1治疗6个月后,两组患者除HDL-C水平较治疗前对比无统计学意义(P>0.05)外,FBG、2 h PG、Hb A1c等控糖指标,TG、TC、LDL-C等脂质生化指标及BMI水平均较治疗前显著降低,其中A组降幅大于B组,差异具有统计学意义(P<0.05);2A组甲级控制率及血糖总控制率分别为70.7%和100.0%,均显著高于B组的37.9%和93.1%(P<0.05);3两组患者治疗期间均无严重不良反应及严重低血糖事件发生,其中A组轻微低血糖发生率为6.9%(4/58),显著低于B组的24.1%(14/58),差异具有统计学意义(P<0.05)。结论:将门冬胰岛素30联合GLP-1受体激动剂方案应用于2型糖尿病患者的临床治疗中,疗效确切,血糖控制效果良好,能有效改善其血脂水平、抑制体重发展,于患者预后提升有利。
Objective: To investigate the effects of glucagon-like peptide-1 (GLP-1) receptor agonist combined with aspart insulin 30 on the glycemic control and body weight of type 2 diabetic patients. Methods: A total of 116 patients with type 2 diabetes mellitus were enrolled in this study. The patients were randomly divided into two groups: study group (group A, n = 58) and control group (group B, n = 58). Group B was treated with insulin aspart 30, and group A with insulin aspart 30 plus liraglutide, all of which were followed up for 24 weeks. The changes of control index, lipid biochemical index and body mass index (BMI) before and after treatment were compared between the two groups. The differences of the control of grade A blood glucose, the total control of blood glucose and the incidence of hypoglycemia were recorded. Results: After 6 months of treatment, except for HDL-C, there was no significant difference between the two groups (P> 0.05). The control indexes such as FBG, 2 h PG and Hb A1c, TG, TC, LDL C and other lipid biochemical indicators and BMI levels were significantly lower than before treatment, of which A group decreased more than B group, the difference was statistically significant (P <0.05); 2A group A control rate and total blood glucose control rates were 70.7 % And 100.0% respectively, which were significantly higher than those in group B (37.9% and 93.1%, respectively) (P <0.05) .3 There were no serious adverse reactions and severe hypoglycemic events during the treatment period in the two groups. The incidence of mild hypoglycemia in group A was 6.9% (4/58), which was significantly lower than that in group B (24.1%, 14/58). The difference was statistically significant (P <0.05). Conclusion: The combination of insulin aspart 30 and GLP-1 receptor agonist in clinical treatment of patients with type 2 diabetes has definite curative effect and good blood sugar control effect, which can effectively improve the level of blood lipid and inhibit the development of body weight, which is beneficial to the prognosis of patients with type 2 diabetes .